Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 47.50%
March 31, 2026 46.10%
December 31, 2025 42.73%
September 30, 2025 46.63%
June 30, 2025 47.07%
March 31, 2025 48.81%
December 31, 2024 43.52%
September 30, 2024 43.49%
June 30, 2024 45.11%
March 31, 2024 48.34%
December 31, 2023 43.99%
September 30, 2023 43.70%
June 30, 2023 48.91%
March 31, 2023 51.95%
December 31, 2022 53.53%
September 30, 2022 52.83%
June 30, 2022 51.54%
March 31, 2022 52.52%
December 31, 2021 52.08%
September 30, 2021 54.33%
June 30, 2021 54.46%
March 31, 2021 52.83%
December 31, 2020 50.22%
September 30, 2020 52.78%
June 30, 2020 52.04%
Date Value
March 31, 2020 51.81%
December 31, 2019 51.99%
September 30, 2019 51.39%
June 30, 2019 51.44%
March 31, 2019 51.20%
December 31, 2018 50.23%
September 30, 2018 52.26%
June 30, 2018 51.21%
March 31, 2018 51.63%
December 31, 2017 51.14%
September 30, 2017 51.02%
June 30, 2017 49.36%
March 31, 2017 49.81%
December 31, 2016 47.70%
September 30, 2016 49.10%
June 30, 2016 48.28%
March 31, 2016 49.29%
December 31, 2015 46.63%
September 30, 2015 51.41%
June 30, 2015 51.03%
March 31, 2015 48.82%
December 31, 2014 47.78%
September 30, 2014 48.45%
June 30, 2014 48.39%
March 31, 2014 48.25%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Evotec SE -1.10%
Gerresheimer AG 10.37%
Lifecore Biomedical, Inc. 35.34%
Mesa Laboratories, Inc. 57.87%
Repligen Corp. 49.25%